Join        Login             Stock Quote

Teva Pharmaceutical (TEVA) PT Cut To $52 By UBS Securities, 'Buy' Maintained

 May 25, 2012 03:49 PM

(By Balaseshan) UBS Securities analyst Marc Goodman lowered his price target on shares of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) to $52 from $60, while maintaining his "Buy" rating.

The company's new Chief Executive Jeremy Levin provided an update on the biz. Levin lowered guidance in the European Union by $1 billion with $600 million from foreign exchange and $400 million from macro issues.

Levin lowered U.S. revenues by $540 million which includes $400 million in generics. This $400 million is due to management being more selective on the products it sells with more focus on profitability.

[Related -Invest In Stocks With A Margin Of Safety To Reduce Risk And Enhance Returns]

The $400 million impact will only affect the bottom line by $0.04. The U.S. generics top line impact is composed of a reduction in inventory of $250 million and $150 million of products that will be delayed.

Management had previously assumed 4%-6% growth in European generics but now is assuming no growth for the rest of 2012.

In Europe, management expects a continual decline of inventory levels throughout 2Q with stabilization in 3Q for an overall 2012 impact of $180 million to $190 million. Management is still planning an analyst day later this year to detail its strategy and the pipeline.

Moving big ships takes time, and honestly after listening to the conference call today and hearing about the problems in both the U.S. and Europe, Goodman has even more questions. But as he works through those questions, the stock does trade at less than 7 times his new 2013 EPS estimate and is just too interesting not to be involved at all.

[Related -Teva Pharmaceutical (TEVA) Dividend Stock Analysis]

The brokerage reduced its 2012 EPS estimate to $5.40 from $5.62 and its 2013 estimate to $5.80 from $6.06.

TEVA is trading down 0.21% at $38.61 on Friday.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageTackling China's Debt Problem: Can Debt-Equity Conversions Help?

China’s high and rising corporate debt problem and how best to address it has received much attention read on...

article imageWill Job Growth Kill The Bear-Market Signal For Stocks?

It’s all about jobs now. Actually, it’s always been about jobs. But the stakes are even higher—perhaps more read on...

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.